Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy.
OBJECTIVE
To report a case of an acquired factor VIII inhibitor associated with the use of interferon-alfa.


METHODS
A 58-year-old white man with newly diagnosed chronic myelogenous leukemia (CML) was initially treated with hydroxyurea. Interferon-alfa therapy was started six weeks later in order to enhance the response, with gradual reduction and eventual discontinuation of hydroxyurea. Interferon-alfa was continued for one year. Following bone marrow aspiration at one year, the patient developed significant bleeding and bruising at the site of extraction. His hemoglobin decreased from 11.3 to 9.3 g/dL and his activated partial thromboplastin time was elevated at 72 seconds. The factor VIII concentration was 0.02 units/mL; factor VIII inhibitor concentration was 58 Bethesda units. A diagnosis of an acquired factor VIII inhibitor was made, and the patient was treated with activated factor VII concentrates and prednisone. Interferon-alfa was discontinued, and the inhibitor subsequently disappeared over the next six weeks. The patient did not have any further bleeding problems.


CONCLUSIONS
Acquired factor VIII inhibitors other than in patients with hemophilia are rare. To date, there are no reported cases of factor VIII inhibitors associated with CML. Moreover, the temporal association with interferon-alfa administration suggests a causal relationship. There are only two previous case reports suggesting interferon-alfa as a cause of factor VIII inhibitors.


CONCLUSIONS
Induction of factor VIII inhibitors is a serious potential complication of therapy with interferon-alfa. We suggest that a diagnosis of an acquired factor VIII inhibitor be considered in patients who experience unexplained bleeding with interferon-alfa therapy.
English
K E
KE
Department of Hematology, University of Western Ontario, London, Canada.
Brien
W F
WF
Howson-Jan
K
K
Kovacs
M J
MJ
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D005169:Factor VIII